The WATCHMAN FLX Pro team (pictured here) has successfully completed 159 WATCHMAN procedures, and will now only use the updated WATCHMAN FLX Pro Device moving forward. (Courtesy Photo) Medical Center ...

MARLBOROUGH, Mass., May 8, 2020 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy of the ...

In the trial, approximately 60% of device patients had their WATCHMAN FLX implant 90-180 days following their ablation procedure. The other nearly 40% of the device patients had the two procedures ...

After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

The Heart Institute of East Texas proudly introduces the latest advancement in cardiac care with the implementation of the Watchman Flx Pro Left Atrial Appendage Occluder implantation technology. This ...

Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...